Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer that happens in your blood and bone marrow, the spongy tissue inside your bones. While the exact cause isn't known, doctors do know that ...

Chronic lymphocytic leukemia (CLL) has a relatively high survival rate. But rates can vary widely, depending on the stage and specific cellular and genetic characteristics of the disease.

Trial results presented at the ASH Annual Meeting 2024 could prompt changes in the treatment of CLL and SLL, experts say.

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

A new analysis shows how Bruton tyrosine kinase (BTK) inhibitors affect full-length BTK conformation by investigating the ...

Researchers sought to determine whether CAR-T therapy would be safe and effective in patients with CLL and Richter transformation.

A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...

The latest news from ASH 2024 focused on chronic lymphocytic leukemia (CLL) including abstracts, features, and helpful ...